Johanna Mercier Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Posted by Francis Steltz on Sep 16th, 2026

Gilead Sciences logo Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $144.22, for a total value of $432,660.00. Following the sale, the insider directly owned 116,684 shares in the company, valued at approximately $16,828,166.48. The trade was a 2.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Johanna Mercier also recently made the following trade(s):

On Monday, August 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $137.64, for a total transaction of $3,853,920.00.

Gilead Sciences Trading Up 0.9%

Shares of Gilead Sciences stock traded up $1.38 during mid-day trading on Wednesday, hitting $147.68. 5,078,675 shares of the stock were exchanged, compared to its average volume of 6,907,595. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The stock has a market capitalization of $183.12 billion, a price-to-earnings ratio of -55.31 and a beta of 0.33. The company has a 50-day simple moving average of $139.02 and a 200 day simple moving average of $136.18. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The company’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.01 earnings per share. Research analysts forecast that Gilead Sciences, Inc. will post -0.48 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is currently -122.85%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Gilead expanded six royalty-free voluntary licensing agreements to include the investigational once-yearly formulation of lenacapavir for HIV pre-exposure prophylaxis. The agreements cover 120 primarily low- and lower-middle-income countries and support manufacturing readiness, technology transfer and future supply planning. The move strengthens Gilead’s global HIV-prevention strategy and could broaden the treatment’s long-term reach if approved. Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Positive Sentiment: Gilead and the Pan American Health Organization agreed to expand access to twice-yearly lenacapavir across Latin America and the Caribbean, adding 14 countries to the company’s access efforts. Broader distribution may support future commercial adoption and reinforces lenacapavir’s growth potential in HIV prevention. Gilead and PAHO Announce Lenacapavir Partnership
Neutral Sentiment: The licensing and PAHO announcements are strategically favorable but are not expected to produce an immediate material revenue contribution, since access agreements emphasize affordability and the once-yearly product remains subject to clinical and regulatory approval.
Negative Sentiment: Gilead’s $0.82-per-share dividend went ex-dividend on September 15. The resulting mechanical share-price adjustment can create short-term pressure, though the payout remains supportive for income-focused investors. Gilead Sciences Dividend Analysis

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. Weiss Ratings upgraded Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Wall Street Zen cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Saturday, September 5th. Daiwa Securities Group cut their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a report on Tuesday, May 19th. Maxim Group raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research report on Wednesday, May 20th. Finally, Needham & Company LLC restated a “buy” rating and issued a $170.00 target price on shares of Gilead Sciences in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $158.78.

View Our Latest Report on Gilead Sciences

Hedge Funds Weigh In On Gilead Sciences

Large investors have recently modified their holdings of the company. Anchor Investment Management LLC grew its stake in shares of Gilead Sciences by 843.7% in the second quarter. Anchor Investment Management LLC now owns 2,831 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 2,531 shares in the last quarter. Bullseye Investment Management LLC acquired a new stake in Gilead Sciences during the 2nd quarter valued at $2,085,000. Talon Private Wealth LLC bought a new position in Gilead Sciences during the second quarter worth $212,000. Core Capital Management & Research inc. acquired a new position in shares of Gilead Sciences in the second quarter valued at $40,000. Finally, Sequoia Financial Advisors LLC increased its holdings in shares of Gilead Sciences by 16.9% in the second quarter. Sequoia Financial Advisors LLC now owns 58,662 shares of the biopharmaceutical company’s stock valued at $7,411,000 after purchasing an additional 8,484 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.